- Home
- GCBC vs XFOR Comparison
GCBC vs XFOR Comparison
Compare GCBC & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GCBC | XFOR |
|---|---|---|
| Founded | 1889 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 378.5M | 324.4M |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | GCBC | XFOR |
|---|---|---|
| Price | $22.61 | $3.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $28.50 |
| AVG Volume (30 Days) | 14.5K | ★ 753.3K |
| Earning Date | 01-22-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | ★ 37.50 | N/A |
| EPS | ★ 1.98 | N/A |
| Revenue | ★ $77,438,000.00 | $33,979,000.00 |
| Revenue This Year | N/A | $1,266.01 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.43 | ★ N/A |
| Revenue Growth | 20.85 | ★ 2925.74 |
| 52 Week Low | $20.00 | $1.35 |
| 52 Week High | $27.62 | $24.43 |
Technical Indicators
Market Signals| Indicator | GCBC | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 41.02 |
| Support Level | $21.79 | $3.73 |
| Resistance Level | $22.66 | $4.24 |
| Average True Range (ATR) | 0.59 | 0.22 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 79.02 | 3.68 |
Price Performance
Historical ComparisonAbout GCBC Greene County Bancorp Inc.
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.